| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5877192 | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
| US6875872 | ASTRAZENECA | Compounds |
May, 2014
(9 years ago) | |
| US5690960 | ASTRAZENECA | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
|
US6875872 (Pediatric) | ASTRAZENECA | Compounds |
Nov, 2014
(9 years ago) | |
|
US5877192 (Pediatric) | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) | |
| US5714504 | ASTRAZENECA | Compositions |
Feb, 2015
(9 years ago) | |
|
US5690960 (Pediatric) | ASTRAZENECA | Pharmaceutical formulation of omeprazole |
May, 2015
(8 years ago) | |
|
US5714504 (Pediatric) | ASTRAZENECA | Compositions |
Aug, 2015
(8 years ago) | |
| US5900424 | ASTRAZENECA | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
|
US5900424 (Pediatric) | ASTRAZENECA | Omeprazole magnesium salt form |
Nov, 2016
(7 years ago) | |
| US7411070 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| US8466175 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| US6369085 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| US6147103 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6166213 | ASTRAZENECA | Omeprazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
| US6191148 | ASTRAZENECA | Omerazole process and compositions thereof |
Oct, 2018
(5 years ago) | |
|
US7411070 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US6369085 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US8466175 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US6147103 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6191148 (Pediatric) | ASTRAZENECA | Omerazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
|
US6166213 (Pediatric) | ASTRAZENECA | Omeprazole process and compositions thereof |
Apr, 2019
(5 years ago) | |
| US6428810 | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
|
US6428810 (Pediatric) | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
May, 2020
(4 years ago) | |
Nexium is owned by Astrazeneca.
Nexium contains Esomeprazole Magnesium.
Nexium has a total of 24 drug patents out of which 24 drug patents have expired.
Expired drug patents of Nexium are:
- US5877192
- US6875872
- US5690960
- US6875872*PED
- US5877192*PED
- US5714504
- US5690960*PED
- US5714504*PED
- US5900424
- US5900424*PED
- US7411070
- US8466175
- US6369085
- US6147103
- US6166213
- US6191148
- US7411070*PED
- US6369085*PED
- US8466175*PED
- US6147103*PED
- US6191148*PED
- US6166213*PED
- US6428810
- US6428810*PED
Nexium was authorised for market use on 15 December, 2011.
Nexium is available in for suspension, delayed release;oral, capsule, delayed rel pellets;oral dosage forms.
Nexium can be used as use for treatment of helicobacter infections, pediatric use aged 1-11 years, gerd and erosive esophagitis, long-term treatment of pathological hypersecretory conditions, treatment of gastroesophageal reflex disease (gerd) and eradication of h.pylori to reduce risk of duodenal ulcer recurrence, pathological hypersecretory conditions, infant use aged 1 month to less than one year, gerd and erosive esophagitis.
The generics of Nexium are possible to be released after 03 May, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-86) | Jun 18, 2012 |
| Pediatric Exclusivity(PED) | Dec 18, 2012 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 15 December, 2011
Treatment: Long-term treatment of pathological hypersecretory conditions; Pediatric use aged 1-11 years, gerd and erosive esophagitis; Infant use aged 1 month to less than one year, gerd and erosive esophagitis...
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL; CAPSULE, DELAYED REL PELLETS;ORAL
NEXIUM family patents
